Drug Profile
Research programme: spinocerebellar degeneration gene therapy - Gene Therapy Research Institution
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Gene Therapy Research Institution
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinocerebellar degeneration
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Spinocerebellar-degeneration in Japan (Parenteral)
- 10 Aug 2017 Preclinical trials in Spinocerebellar degeneration in Japan (Parenteral) (Gene Therapy Research Institution pipeline, August 2017)
- 10 Aug 2017 Gene Therapy Research Institution plans phase I/II trials in 2020 (Gene Therapy Research Institution pipeline, August 2017)